tiprankstipranks
Trending News
More News >
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP

Crispr Therapeutics AG (CRSP) AI Stock Analysis

Compare
9,145 Followers

Top Page

CR

Crispr Therapeutics AG

(NASDAQ:CRSP)

51Neutral
Crispr Therapeutics AG is currently facing substantial financial and operational challenges, reflected in its negative income and cash flow figures. Despite a strong balance sheet, the company is experiencing downward momentum in its stock price, as indicated by technical analysis. Valuation metrics further highlight ongoing struggles, with a negative P/E ratio and no dividend yield. These factors combine to create a cautious investment outlook.
Positive Factors
Financial Position
High interest rates benefit Crispr's large cash position.
Pipeline and Partnerships
CRSP is being upgraded ahead of key catalysts that could usher in a new era for the company.
Product Launch
Casgevy's accelerating launch is supported by strong payer coverage, especially in the US, Middle East, and EU.
Negative Factors
Market Competition
Increasing competition in China is mainly limited to biologics and less advanced modalities, which doesn't significantly impact Crispr.
Regulatory Environment
Crispr does not have programs entering regulatory submission where risk is the highest.

Crispr Therapeutics AG (CRSP) vs. S&P 500 (SPY)

Crispr Therapeutics AG Business Overview & Revenue Model

Company DescriptionCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
How the Company Makes MoneyCrispr Therapeutics AG generates revenue through a combination of collaboration agreements, milestone payments, and potential royalties from its partnerships with other biotechnology and pharmaceutical companies. Key revenue streams include collaborations with industry leaders like Vertex Pharmaceuticals, with whom it co-develops treatments for genetic diseases. The company also receives research funding and upfront payments from these collaborations, contributing to its earnings. Additionally, Crispr Therapeutics may generate future revenue from the commercialization of its proprietary therapies once they receive regulatory approval and are brought to market.

Crispr Therapeutics AG Financial Statement Overview

Summary
Crispr Therapeutics AG faces significant financial challenges, particularly in revenue generation and profitability. Despite a strong balance sheet with substantial equity and cash reserves, the company struggles with negative income and cash flow metrics. These issues highlight the need for improved operational efficiency and revenue growth strategies to ensure financial sustainability.
Income Statement
45
Neutral
Crispr Therapeutics AG has shown significant volatility in revenue and profit margins. The most recent annual report indicates a drastic revenue decline compared to previous years, with a sharp drop from 2021 to 2024. Gross and net profit margins have turned negative, highlighting operational challenges and high expenses relative to revenue. The TTM data shows a negative EBIT and EBITDA margin, indicating operational inefficiencies and ongoing financial struggles.
Balance Sheet
65
Positive
The company maintains a strong equity position with a high equity ratio, suggesting stability in its capital structure. While the debt-to-equity ratio is relatively low, indicating manageable leverage, the stockholders' equity has slightly declined over the years. The balance sheet reflects a solid cash position, which is crucial for a biotech firm investing in R&D, despite the negative net income.
Cash Flow
50
Neutral
Crispr Therapeutics AG exhibits a negative free cash flow trend, with operating cash flows consistently negative over recent years. This indicates potential liquidity challenges. The free cash flow to net income ratio is also negative, underscoring ongoing cash management issues. The cash flow from financing has been positive, which may provide temporary relief but signifies reliance on external funding.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
35.00M371.21M436.00K913.08M543.00K
Gross Profit
37.31M240.96M-109.81M895.13M-268.86M
EBIT
-466.57M-222.54M-673.16M373.53M-354.44M
EBITDA
-466.57M-202.70M-648.99M391.48M-345.25M
Net Income Common Stockholders
-366.25M-153.61M-650.17M377.66M-348.87M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.90B1.69B1.82B2.38B1.69B
Total Assets
2.24B2.23B2.24B2.75B1.83B
Total Debt
223.69M238.63M244.02M225.03M61.43M
Net Debt
-74.56M-150.84M32.14M-698.00M-1.11B
Total Liabilities
309.95M346.77M367.58M352.42M163.73M
Stockholders Equity
1.93B1.88B1.88B2.40B1.66B
Cash FlowFree Cash Flow
-144.68M-272.35M-532.93M457.27M-256.72M
Operating Cash Flow
-142.77M-260.38M-495.74M538.97M-238.37M
Investing Cash Flow
-280.48M374.65M-258.65M-1.04B-541.17M
Financing Cash Flow
331.98M62.66M38.59M250.94M1.02B

Crispr Therapeutics AG Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price38.27
Price Trends
50DMA
40.95
Negative
100DMA
42.05
Negative
200DMA
45.79
Negative
Market Momentum
MACD
-0.29
Negative
RSI
53.36
Neutral
STOCH
78.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Neutral. The current price of 38.27 is above the 20-day moving average (MA) of 36.09, below the 50-day MA of 40.95, and below the 200-day MA of 45.79, indicating a neutral trend. The MACD of -0.29 indicates Negative momentum. The RSI at 53.36 is Neutral, neither overbought nor oversold. The STOCH value of 78.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRSP.

Crispr Therapeutics AG Risk Analysis

Crispr Therapeutics AG disclosed 85 risk factors in its most recent earnings report. Crispr Therapeutics AG reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Crispr Therapeutics AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$5.31B3.33-39.82%2.92%17.95%1.84%
51
Neutral
$3.37B-19.20%-89.95%-123.71%
47
Neutral
$2.03B-43.94%-83.18%-144.95%
45
Neutral
$176.85M-187.83%-67.20%64.66%
40
Underperform
$846.77M-54.00%59.55%3.09%
38
Underperform
$513.24M-36.36%174.98%25.06%
33
Underperform
$134.77M-98.10%-58.64%-40.05%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CRSP
Crispr Therapeutics AG
38.27
-15.64
-29.01%
SGMO
Sangamo Biosciences
0.79
0.27
51.92%
EDIT
Editas Medicine
1.54
-3.78
-71.05%
NTLA
Intellia Therapeutics
8.31
-12.45
-59.97%
BEAM
Beam Therapeutics
19.52
-1.86
-8.70%
VERV
Verve Therapeutics
5.76
-0.40
-6.49%

Crispr Therapeutics AG Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
CRISPR Therapeutics COO Julianne Bruno Resigns
Neutral
Mar 26, 2025

On March 24, 2025, Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics, announced her resignation effective April 11, 2025, to pursue external opportunities. Her departure is not due to any disagreement with the company. Bruno has been a key figure in advancing the company’s hematology and oncology programs and other initiatives. Her resignation marks a significant transition for CRISPR Therapeutics, which continues to strengthen its position in the biopharmaceutical industry through strategic partnerships and innovative gene-editing solutions.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.